Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Article Oncology

Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).

Yohann Loriot et al.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

Arlene O. Siefker-Radtke et al.

Summary: This study evaluated the long-term efficacy and safety of Erdafitinib in patients with locally advanced or metastatic urothelial carcinoma. The results showed consistent activity and manageable safety profile in these patients.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles et al.

Summary: The study examined the outcomes of using pembrolizumab alone or combined with chemotherapy as first-line treatment for advanced urothelial carcinoma, and found that the addition of pembrolizumab to platinum-based chemotherapy did not significantly improve efficacy. Safety was assessed and the study concluded that this combination treatment should not be widely adopted for this type of cancer.

LANCET ONCOLOGY (2021)

添加到收藏夹

Review Oncology